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ABSTRACT: Enantiomerically pure tailor-made amino acids are in extremely high demand
in nearly every sector of the health-related industries. In particular, the rapidly growing
number of amino-acid-based pharmaceuticals calls for the development of advanced
synthetic approaches featuring practicality and commercial viability. Here we provide a brief
summary of the development of axially chiral tridentate Hamari ligands and their application
for general asymmetric synthesis of various structural types of amino acids. The
methodological diversity includes: dynamic kinetic resolution and (S)-/(R)-interconversion
of unprotected amino acids and homologation of nucleophilic glycine equivalents via alkyl
halide alkylation reactions as well as multiple-step transformations allowing preparation of
polyfunctional and cyclic derivatives. The practicality of these methods is critically discussed.
1. INTRODUCTION
Amino acids (AAs) are among a few fundamental “building
blocks of life” and have played a significant role in drug
discovery from the earliest days of modern pharmaceutical
science. Specially designed, tailor-made AAs are indispensable
components of modern medicinal chemistry and are becoming
increasingly prominent in new pharmaceuticals and medical
formulations. Moreover, the growing recognition of peptides
and peptidomimetics as preferred drugs evidently advocates for
the growing role of tailor-made AAs in the modern
pharmaceutical industry.1 The synthesis of AAs is a well-
developed discipline offering a plethora of various methodo-
logical approaches. Nonetheless, from the standpoint of
practicality, there still is an urgent need for the development
of advanced synthetic methods suitable for large-scale
production of tailor-made AAs of high chemical and
enantiomeric purity.2 In this mini-review, we would like to
acquaint the readers with the most recent developments in the
field dealing with the design of new chiral nucleophilic glycine
equivalents as versatile reagents for general asymmetric
synthesis of tailor-made AAs. In particular, we focus on the
chiral Hamari ligands and glycine derivatives, as the most
promising reagents for large-scale practical solutions.
2. VERSATILITY OF SYNTHETIC APPLICATION OF
NUCLEOPHILIC GLYCINE EQUIVALENTS
The use of Schiff bases of glycine derivatives 1 (Figure 1) for
the synthesis of AAs was introduced by the Stork group in
1976.3 Since then, these derivatives have been fully appreciated
as a preferred type of nucleophilic glycine equivalent. Features
such as structural simplicity, ready availability, high C−H
acidity, and chemical versatility are very synthetically attractive,
especially from the standpoint of practicality.
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Figure 1. Achiral 1 and chiral 2 and 3 equivalents of nucleophilic
glycine.
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Most notably, chiral Schiff base modifications 2 and 3 were
reported in 1976 by Yamada4 and in 1983 by Belokon5 groups,
correspondingly. The latter, square-planar Ni(II) complex 3
was shown (Scheme 1) to serve as a chiral nucleophilic glycine
equivalent in reactions with numerous electrophilic reagents.6
Most typically used reaction types are represented by alkyl
halide alkylations 4,7 dialkylations 5,8 secondary alkyl halide
alkylations 6,9 and bisalkylations 710 and aldol 8,11 Mannich
9,12 and Michael 1013 addition reactions. Multiple step
processes, like addition−cyclization, leading to pyroglutamic
acids 11,14 β-substituted prolines 12,15 and derivatives of 1-
amino-2-vinylcyclopropane-1-carboxylic acid 1316 can also be
conveniently performed.
However, despite this extraordinary synthetic versatility of
glycine complex 3, the potential of its application for large-
scale synthesis of tailor-made AAs is rather limited due to the
practically unsatisfactory levels of stereocontrol (∼90% de),
partial racemization of the proline moiety, and problematic
isolation of the target AAs.
3. NEW GENERATION OF CHIRAL SCHIFF BASE
GLYCINE NI(II) COMPLEXES
Over the last five years, significant progress has been made in
the design of structurally novel chiral tridentate ligands and the
corresponding Ni(II) complexes, allowing us to address the
synthetic shortcomings of complex 3. As presented in Figure 2,
proline-derived complexes 1417 and 1518 show noticeably
improved diastereoselectivity in the reactions with electro-
philes. Furthermore, the trichloro derivative 14 can be used for
the preparation of β-AAs. However, under strongly basic
reaction conditions, complexes 14 and 15 are prone to
racemization at the proline moiety, limiting their practical
application
The structural type of complex 16,19 possessing a stereo-
genic nitrogen, racemization-stable secondary amine moiety,
and an extremely lipophilic adamantyl group, offers an
exceptionally practical solution for the preparation of AAs via
a rare case of second-order asymmetric transformation control.
Nonetheless, the synthetic range of complex 16 is limited to
mostly aromatic AA types. The most exciting success in the
structural design of new chiral ligands and the corresponding
glycine complexes has been achieved with the recent
development of (3Z,5Z)-2,7-dihydro-1H-azepine-derived Ni-
(II) 17.20 Similar to the new generation of nucleophilic glycine
equivalents 14, 15, and 16, the Hamari-Gly complex 17 allows
us to achieve very high levels of diastereocontrol (up to >99:1)
reproducible on the large scale. However, the major advantage
of reagent 17 is the indestructible axial chirality, affording
unlimited recycling and reuse of the chiral auxiliary. This
particular feature renders the whole process, in terms of the
cost and efficiency, comparable to or superior over catalytic
and biocatalytic approaches.
4. DESIGN AND LARGE-SCALE SYNTHESIS OF
CHIRAL TRIDENTATE (R)- AND (S)-HAMARI
LIGANDS
The recently reported large-scale synthesis of Hamari ligand 23
is presented in Scheme 2. The process begins with
esterification of enantiomerically pure BINOL 18 by the
action of Tf2O. The activated ester 19 is reacted next with
MeMgI to afford dimethyl derivative 20 with quantitative yield.
The subsequent radical bromination gives rise to the dibromo
intermediate 21 with a moderate 71% yield.20
Scheme 1. Versatility of Chiral Nucleophilic Glycine
Equivalent 3 for the Preparation of Tailor-Made AAs of
General Types 4−13
Figure 2. Structures of structurally novel chiral nucleophilic glycine equivalents, available in both enantiomeric forms.
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The final step of the process is the alkylation of the specially
designed glycine-o-amino-benzophenone adduct 22 using
dibromide 21. The reaction is conducted in isopropyl acetate
using aqueous sodium carbonate as a base. The resulting
Hamari ligand 23 is isolated by filtration as a pale-yellow solid
with 93% yield. Using this procedure, the Hamari ligand 23
can be prepared on a kilogram scale in both (S)- and (R)-
enantiomeric forms.20
5. DYNAMIC KINETIC RESOLUTION AND
(S)-/(R)-INTERCONVERSION OF UNPROTECTED
α-AAS
One of the notable applications of Hamari ligand 23 is the
dynamic kinetic resolution of unprotected amino acids. The
overall process, presented in Scheme 3, includes the formation
of Ni(II) complex intermediates 25 followed by their
disassembly to release the target AAs 24 and recycling of the
ligand 23.21
The first step of the process, the reaction of Hamari ligand
23 with racemic AAs, is conducted in methanol under
moderate heating (60−70 °C) in the presence of Ni(OAc)2
and K2CO3. This step includes in situ formation of the
corresponding Schiff base and ionization of the amide and
carboxylic groups followed by chelation of the Ni(II) ions into
square-planar complexes 25. Under the basic reaction
conditions, the α-stereogenic carbon is relatively configura-
tionally unstable, allowing for thermodynamic control of the
diastereomeric preferences, giving rise to (R)-absolute
configuration of the amino acid in complexes with (S)-axial
chirality and, correspondingly, (S)-AA 24 induced by (R)-axial
chirality. The diastereoselectivity is slightly dependent on the
AA side chain and varies between 95 and 97% de.
Diastereomeric enrichment to >99% de usually takes place at
the workup stage by precipitation of products 25 from aqueous
methanol solutions. The chemical yields range from 95% to
quantitative. The structural generality of this method is
exceptionally high as polyfunctional AAs containing OH,
NH2, COOH, and S-Me groups can be used without any
additional protection. About 50 examples of structurally
diverse AAs have been successfully prepared so far in
enantiomerically pure form using this method.22 Disassembly
of complexes 25 is conducted by heating in HCl/MeOH,
affording target AAs 24 along with recovery of chemically and
stereochemically uncompromised chiral ligand 23. Impor-
tantly, this method for chemical dynamic kinetic resolution and
(S)-/(R)-interconversion of unprotected α-AAs can be
successfully used for preparation of the corresponding α-
deuterated derivatives 26, a very useful special type of
isotopically labeled AAs for mechanistic studies. The required
modification is a simple application of deuterated methanol at
the stage of complex 25 formation, allowing for up to 90% of
the deuteration in the α-position.23
6. SYNTHESIS OF CHIRAL HAMARI-GLY AND ITS
ASYMMETRIC ALKYLATIONS
Another avenue of application of Hamari ligands (S)- and (R)-
23 for general asymmetric synthesis of tailor-made AAs is their
transformation to the corresponding glycine Schiff base
complexes 17 followed by their homologation with various
electrophiles.24 As presented in Scheme 4, in the presence of
base, Hamari ligand 23 reacts with glycine and a source of
Ni(II) ions, forming the square-planar Hamari-Gly complex 17
with over 95% yield.
Due to the very high reactivity of the glycine methylene in
complex 17, the alkyl halide alkylations can be conducted in
NaOMe/MeOH at ambient temperature. These conditions are
limited to activated alkyl halides; however, the observed
diastereoselectivity is exceptionally high (∼99:1), allowing for
a convenient preparation of various aromatic and hetero-
aromatic tailor-made AAs. A more general alkylation protocol
is currently under development and shall include polar aprotic
solvent and strong inorganic bases as shown (vide infra) in the
example of the asymmetric synthesis of α-(methyl)cysteine
derivatives.
7. ASYMMETRIC SYNTHESIS OF (2S)- AND
(2R)-α-(METHYL)CYSTEINE DERIVATIVES
Construction of the stereogenic quaternary carbon in α,α-
disubstituted AAs usually entails investigation of two possible
approaches based on which of the two side chains is
Scheme 2. Large-Scale (kg) Synthesis of the Hamari Ligand
(R)- or (S)-23a
a(a) Tf2O, pyridine, toluene. (b) NiCl2(dppp)2, MeMgI, MTBE. (c)
1,3-Dibromo-5,5-dimethylhydantoin, AIBN, ethyl acetate. (d)
Na2CO3, iPrOAc.
Scheme 3. Asymmetric Preparation of AAs and Their α-
Deuterated Derivatives via Chemical Dynamic Kinetic
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introduced first. As shown in Scheme 5, asymmetric synthesis
of α-(methyl)cysteine can be accomplished by methylation of
cysteine Schiff base complex 30 or thiomethylation of alanine-
derived complex 32.
In the first line of inquiry, the Hamari ligand 23 was reacted
with S-protected racemic cysteine 28 to produce the
corresponding Schiff base Ni(II) complex 30. Quite
unexpectedly, attempts to methylate complex 30 under basic
conditions resulted in nearly quantitative formation of
dehydroalanine derivative 31. It was found that the
corresponding enolate derived from 30 undergoes a rapid
stabilization by ejecting the S-CH2−Ph anion, giving rise to
Scheme 4. General Asymmetric Synthesis of Tailor-Made AAs via Alkylation of Hamari-Gly 17
Scheme 5. Two Alkylation Options for the Construction of Quaternary of (2S)- and (2R)-α-(Methyl)cysteine Derivatives
Using Hamari Ligand 23
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dehydroalanine complex 31.25 The second approach via
formation of the intermediate alanine Schiff base complex 32
was rather successful. The thiomethylation of 32 with reagent
33 was conducted in DMF using NaOH as base. α-
(Methyl)cysteine derivative 34 was isolated with up to 75%
yield and about 9:1 diastereomeric ratio. While the observed
level of the stereochemical outcome, from the general
standpoint, is rather moderate, it is on par or better with
literature examples on this type of asymmetric alkylation.
Moreover, this method has a significant advantage of
operationally convenient and scalable reaction conditions.
Furthermore, the diastereomeric purity of 34 can be increased
by crystallization of the crude product. The target AA was
isolated from diastereomerically pure complex 34 with >95%
yield and >99% ee. Once again, it should be emphasized that
the Hamari ligand was recovered stereochemically intact. In
general, α-(methyl)cysteine is difficult to obtain by other
methods, and the current interest in this tailor-made AA is
derived from its application in the design of a new generation
of histone deacetylase inhibitors as emerging therapeutics for
cutaneous T-cell lymphoma.
8. ASYMMETRIC SYNTHESIS OF
(1R,2S)-1-AMINO-2-VINYLCYCLOPROPANECAR-
BOXYLIC ACID
Another example of the Hamari ligand application for
asymmetric synthesis of tailor-made AAs is illustrated (Scheme
6) by the preparation of structurally complex (1R,2S)-1-amino-
2-vinylcyclopropanecarboxylic acid, the essential pharmaco-
phoric unit in a new generation of highly potent hepatitis C
virus (HCV) NS3/4A protease inhibitors. As presented in
Scheme 6, the whole process includes two steps via SN2 and
SN2′ alkylation. Taking advantage of activating the allylic
reactivity of dibromide 36, the first SN2 alkylation step was
conducted under very mild phase-transfer catalysis (PTC)
conditions, allowing the preparation of intermediate 37 with
over 90% yield.26
The second step, the internal SN2′ alkylation of 37 to 38,
was conducted under more basic reaction conditions using
THF as a solvent and NaO-t-Bu as a base. The reaction
occurred with excellent yield (>90%) and diastereoselectivity
(>98% de). After the standard disassembly procedure, the
target AA 39 was isolated, as the N-Boc derivative, in
enantiomerically pure form (>99% ee), along with the recovery
and recycling of the Hamari ligand (S)-23.26 It should be
mentioned that the obtained values of the stereochemical
outcome are actually the highest reported in the literature for
this type of internal SN2′ cyclizations.
9. CONCLUSIONS
We trust that the data briefly presented here on the chemistry
of recently developed chiral Hamari ligands and Hamari-Gly
complexes convincingly demonstrate the synthetic potential of
these compounds for general asymmetric synthesis of tailor-
made AAs. The overall low cost of this approach is provided by
virtually unlimited recyclability of the ligands due to their
configurational stability. The operational ease of all trans-
formations coupled with its predictable reactivity and stereo-
chemical outcome in complex settings bode well for the
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